Drug intelligence / Profile preview

WE

Development stage: Preclinical
Lead developer: JW Theriac Pharmaceutical
Modality: Small Molecules

Overview

WE is an undisclosed **small-molecule dual inhibitor of Wee1 and Myt1** being developed by **JW Theriac** for **cancer**. The program appears on the company's pipeline as a **preclinical** oncology asset. By simultaneously inhibiting the cell-cycle checkpoint kinases Wee1 and Myt1, the molecule is intended to disrupt checkpoint control and force tumor cells through aberrant mitotic progression, a strategy consistent with targeted anticancer therapy.

Other names: JW Theriac Pharmaceuticals Wee1 Myt1 small molecule CancerWee1 Myt1 dual inhibitorWee-1 Myt1 dual inhibitorWee 1 Myt1 dual inhibitor

Targets

PKMYT1 (Protein kinase membrane associated tyrosine/threonine 1)WEE1 (WEE1 G2 checkpoint kinase)

Beyond the preview

Go deeper on WE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WE.

Explore the full profile